South Korean drugmaker GC Biopharma formed a partnership with Kanaph Therapeutics to develop a bispecific antibody-drug conjugate targeting solid tumors, expanding its oncology portfolio.
The collaboration gives GC Biopharma the option to participate in development once Kanaph’s ADC candidate meets undisclosed criteria. Both companies kept financial terms and specific targets confidential.
The deal marks GC Biopharma’s strategic push into the growing ADC market, which analysts expect to reach $30 billion globally by 2028. ADCs combine antibodies with cancer-killing drugs to target tumor cells while sparing healthy tissue.
GC Biopharma’s R&D head Jung Jae-wook highlighted the agreement’s potential to address unmet needs in cancer treatment, while Kanaph CEO Lee Byung-chul emphasized their focus on developing differentiated therapies.
The partnership aligns with rising interest in bispecific ADCs, which can target multiple proteins on cancer cells. Several major pharmaceutical companies have recently increased investments in this technology through similar development deals.
